Login / Register

The leading independent clinical services provider

Research

Interface Clinical Research, a division of Interface Clinical Services, has established a new model to provide pharma companies and CROs with an efficient service to recruit and run phase III and IV primary care, clinical trials.

Delivered through their clinical pharmacist team, Interface apply their experience of running patient clinics in primary care to achieve improved acquisition, productivity and retention within the clinical research market.

Interface Clinical Research has exposure to 41% of the UK population and almost 3,500 potential sites each year. We experience working with some of the largest healthcare companies in the world, with Interface currently contracted to 7 of the top 20 global pharmaceutical companies as well as partnering directly with the NHS. Interface Clinical Research is perfectly positioned to quickly meet the needs of the client and identify suitable locations to deliver the required patient groups.


Interface work with CROs and pharma companies to manage clinical trials from initial feasibility through to the provision of data; this includes:

Recruitment - Interface partners with thousands of GP practices across the UK, many of which are keen to participate in clinical research studies.

Enrolment and randomisation – This is carried out by Interface’s experienced research team.

The running of the clinical trial - Patients visit their local GP practice where they are seen by an Interface Good Clinical Practice (GCP) trained clinical investigator

Patient management and retention – Interface has a specialised team which interacts with the patient on all aspects of the study and includes an ongoing retention programme.

Data collection – Dealing with patient data is a core function of Interface's business, enhanced through personnel profiling, training and rigorous policies and procedures.

Success

Cookies

This website uses cookies. You can read more information about why we do this, and what they are used for here.

Accept Decline